Association of IRS1 Gly972Arg and IRS2 Gly1057Asp polymorphisms with gastric cancer in Turkish subjects

Gorgisen,Gokhan; Karatas,Ugur; Ates,Can; Oksuz,Murat; Gulacar,Ismail Musab

doi:10.3892/ol.2020.11717

Association of IRS1 Gly972Arg and IRS2 Gly1057Asp polymorphisms with gastric cancer in Turkish subjects

Authors:
- Gokhan Gorgisen
- Ugur Karatas
- Can Ates
- Murat Oksuz
- Ismail Musab Gulacar
View Affiliations

Affiliations: Department of Medical Biology, Faculty of Medicine, Van Yuzuncu Yil University, Van 65080, Turkey, Department of Biostatistics, Faculty of Medicine, Van Yuzuncu Yil University, Van 65080, Turkey, Department of Gastroenterology, Private Adana Ortadogu Hospital, Adana 67055, Turkey
Published online on: June 9, 2020 https://doi.org/10.3892/ol.2020.11717
Pages: 2016-2020

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin receptor substrate (IRS) proteins are cytoplasmic adaptors that transmit the signal from the IR and insulin‑like growth factor‑1 receptor to effector proteins. Overexpression of IRS proteins has been indicated to be linked to cancer development. In addition to their expression profiles, studies have indicated that polymorphisms of IRS1 and IRS2 are also associated with the susceptibility to numerous cancer types. IRS1 Gly972Arg and IRS2 Gly1057Asp are the common variants of these genes. The present study aimed to determine the association of IRS1 Gly972Arg and IRS2 Gly1057Asp polymorphisms with gastric cancer development. The study included 100 patients with gastric cancer and 100 controls. Single‑nucleotide polymorphisms were detected by real‑time PCR using Taqman assays. The results suggested that in individuals with the IRS1 Gly/Arg genotype, the odds of having gastric cancer was increased by 7.891‑fold (95% CI: 3.251‑19.154, P<0.001) and in individuals with the IRS1 Arg/Arg genotype, it was increased by 22.716‑fold (95% CI: 6.311‑81.761, P<0.001) compared with those with the IRS1 Gly/Gly genotype. Although the IRS2 Gly1057Asp genotype analysis suggested that subjects with the Asp/Asp genotype had a 2,311‑fold increased odds of having gastric cancer compared to those with the Gly/Gly genotype, the result was not statistically significant (95% CI: 0.800‑6.678, P=0.122). The combined effects of the IRS1 and IRS2 variants on gastric cancer were also determined. The results suggested that individuals with Gly/Arg+Gly/Asp and Gly/Arg+Asp/Asp genotypes had a higher odds of having gastric cancer compared to individuals of the Gly/Gly+Gly/Gly genotype (P=0.001 and P=0.027, respectively). In conclusion, the present results suggested that the IRS1 Gly972Arg and IRS2 Gly1057Asp variations may be associated with an increased susceptibility to develop gastric cancer. Further studies with larger sample sizes are required to support the present results and to explore the use of these variations as a biomarker for gastric cancer.

View Figures

View References

1	Rawla P and Barsouk A: Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz Gastroenterol. 14:26–38. 2019.PubMed/NCBI
2	Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and Yee D: Diabetes and cancer: A consensus report. Diabetes Care. 33:1674–1685. 2010. View Article : Google Scholar : PubMed/NCBI
3	Saarela K, Tuomilehto J, Sund R, Keskimäki I, Hartikainen S and Pukkala E: Cancer incidence among Finnish people with type 2 diabetes during 1989–2014. Eur J Epidemiol. 34:259–265. 2019. View Article : Google Scholar : PubMed/NCBI
4	Abudawood M: Diabetes and cancer: A comprehensive review. J Res Med Sci. 24:942019. View Article : Google Scholar : PubMed/NCBI
5	Gorgisen G, Gulacar IM and Ozes ON: The role of insulin receptor substrate (IRS) proteins in oncogenic transformation. Cell Mol Biol (Noisy-le-grand). 63:1–5. 2017. View Article : Google Scholar : PubMed/NCBI
6	Shaw LM: The insulin receptor substrate (IRS) proteins: At the intersection of metabolism and cancer. Cell Cycle. 10:1750–1756. 2011. View Article : Google Scholar : PubMed/NCBI
7	Gibson SL, Ma Z and Shaw LM: Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle. 6:631–637. 2007. View Article : Google Scholar : PubMed/NCBI
8	Mardilovich K, Pankratz SL and Shaw LM: Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 7:142009. View Article : Google Scholar : PubMed/NCBI
9	Gorgisen G, Hapil FZ, Yilmaz O, Cetin Z, Pehlivanoglu S, Ozbudak IH, Erdogan A and Ozes ON: Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer. Genet Mol Bio. 42:15–25. 2019. View Article : Google Scholar
10	Lin MW, Huang MF and Wu MH: Association of Gly972Arg variant of insulin receptor subtrate-1 and Gly1057Asp variant of insulin receptor subtrate-2 with polycystic ovary syndrome in the Chinese population. J Ovarian Res. 7:922014. View Article : Google Scholar : PubMed/NCBI
11	Gelaleti RB, Damasceno DC, Salvadori DM, Marcondes JP, Lima PH, Morceli G, Calderon IM and Rudge MV: IRS-1 gene polymorphism and DNA damage in pregnant women with diabetes or mild gestational hyperglycemia. Diabetol Metab Syndr. 7:302015. View Article : Google Scholar : PubMed/NCBI
12	Zhang H, Wang A, Ma H and Xu Y: Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk. Tumour Biol. 34:2929–2936. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ayaz L, Karakaş Çelik S and Cayan F: The G1057D polymorphism of insulin receptor substrate-2 associated with gestational diabetes mellitus. Gynecol Endocrinol. 30:165–168. 2014. View Article : Google Scholar : PubMed/NCBI
14	Christopoulos P, Mastorakos G, Gazouli M, Deligeoroglou E, Katsikis I, Diamanti-Kandarakis E, Panidis D and Creatsas G: Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact? Gynecol Endocrinol. 26:698–703. 2010. View Article : Google Scholar : PubMed/NCBI
15	Carvalheira JB, Ribeiro EB, Folli F, Velloso LA and Saad MJ: Interaction between leptin and insulin signaling pathways differentially affects JAK-STAT and PI 3-kinase-mediated signaling in rat liver. Biol Chem. 384:151–159. 2003. View Article : Google Scholar : PubMed/NCBI
16	D'Alfonso R, Marini MA, Frittitta L, Sorge R, Frontoni S, Porzio O, Mariani LM, Lauro D, Gambardella S, Trischitta V, et al: Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. J Clin Endocrinol Metab. 88:317–322. 2003. View Article : Google Scholar : PubMed/NCBI
17	Arikoglu H, Aksoy Hepdogru M, Erkoc Kaya D, Asik A, Ipekci SH and Iscioglu F: IRS1 gene polymorphisms Gly972Arg and Ala513Pro are not associated with insulin resistance and type 2 diabetes risk in non-obese Turkish population. Meta Gene. 2:579–585. 2014. View Article : Google Scholar : PubMed/NCBI
18	Brancati FL, Kao WL, Folsom AR, Watson RL and Szklo M: Incident type 2 diabetes mellitus in African American and white adults: The atherosclerosis risk in communities study. JAMA. 283:2253–2259. 2000. View Article : Google Scholar : PubMed/NCBI
19	Thameem F, Puppala S, Schneider J, Bhandari B, Arya R, Arar NH, Vasylyeva TL, Farook VS, Fowler S, Almasy L, et al: The Gly(972)Arg variant of human IRS1 gene is associated with variation in glomerular filtration rate likely through impaired insulin receptor signaling. Diabetes. 61:2385–2393. 2012. View Article : Google Scholar : PubMed/NCBI
20	Li P, Wang L, Liu L, Jiang H, Ma C and Hao T: Association between IRS-1 Gly972Arg polymorphism and colorectal cancer risk. Tumour Biol. 35:6581–6585. 2014. View Article : Google Scholar : PubMed/NCBI
21	Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P and Ma J: No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 68:1416–1420. 2008. View Article : Google Scholar : PubMed/NCBI
22	Neuhausen SL, Slattery ML, Garner CP, Ding YC, Hoffman M and Brothman AR: Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: Strong association of IRS1 G972R variant and cancer risk. Prostate. 64:168–174. 2005. View Article : Google Scholar : PubMed/NCBI
23	Cayan F, Tok E, Aras-Ateş N, Ayaz L, Akbay E, Gen R, Karakaş S and Dilek S: Insulin receptor substrate 2 gene polymorphism: Is it associated with endometrial cancer? Gynecol Endocrinol. 26:378–382. 2010. View Article : Google Scholar : PubMed/NCBI
24	Çayan F, Dilek S, Ramazan G, Akbay E, Aras-Ateş N and Ayaz L: Association of insulin receptor substrate-2 gene polymorphism with ovarian cancer. Balkan Med J. 28:14–17. 2011.
25	Yukseloglu EH, Celik SK, Kucuk MU, Yalin E, Ozkal SS, Ates C, Berkoz M, Yalin S and Ates NA: IRS-2 G1057D polymorphism in Turkish patients with colorectal cancer. Prz Gastroenterol. 9:88–92. 2014.PubMed/NCBI
26	Yin J, Zhang Z, Zheng H and Xu L: IRS-2 rs1805097 polymorphism is associated with the decreased risk of colorectal cancer. Oncotarget. 8:25107–25114. 2017. View Article : Google Scholar : PubMed/NCBI
27	Hu Y, Zhou M, Zhang K, Kong X, Hu X, Li K and Liu L: Lack of association between insulin receptor substrate2 rs1805097 polymorphism and the risk of colorectal and breast cancer: A meta-analysis. PLoS One. 9:e869112014. View Article : Google Scholar : PubMed/NCBI
28	Ijaz A, Babar S, Sarwar S, Shahid SU and Shabana: The combined role of allelic variants of IRS-1 and IRS-2 genes in susceptibility to type 2 diabetes in the Punjabi Pakistani subjects. Diabetol Metab Syndr. 11:642019. View Article : Google Scholar : PubMed/NCBI